Search results for "type II"

showing 10 items of 607 documents

1H, 13C, and 15N NMR chemical shift assignment of the complex formed by the first EPEC EspF repeat and N-WASP GTPase binding domain

2021

AbstractLEE-encoded effector EspF (EspF) is an effector protein part of enteropathogenic Escherichia coli’s (EPEC’s) arsenal for intestinal infection. This intrinsically disordered protein contains three highly conserved repeats which together compose over half of the protein’s complete amino acid sequence. EPEC uses EspF to hijack host proteins in order to promote infection. In the attack EspF is translocated, together with other effector proteins, to host cell via type III secretion system. Inside host EspF stimulates actin polymerization by interacting with Neural Wiskott-Aldrich syndrome protein (N-WASP), a regulator in actin polymerization machinery. It is presumed that EspF acts by di…

030303 biophysicsRegulatormacromolecular substancesBiochemistryArticleType three secretion system03 medical and health sciencesStructural BiologyEnteropathogenic Escherichia coliNMR-spektroskopiaN-WASPPeptide sequenceActin030304 developmental biologysolution NMRSolution NMR0303 health sciencesEffectorChemistryResonance assignmentsresonance assignmentsNuclear magnetic resonance spectroscopyintrinsically disordered protein3. Good healthCell biologytype III secretion systemType III secretion systemIntrinsically disordered proteinEPEC EspFproteiinitGTPase bindingBiomolecular Nmr Assignments
researchProduct

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19

2021

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)LipoproteinsEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Familial hypercholesterolemia030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicinePandemicInternal MedicinemedicineHumansHyperlipoproteinemia Type IILife StylePandemicsLetter to the Editor030304 developmental biology0303 health sciencesNutrition and DieteticsSARS-CoV-2Life stylebusiness.industryHomozygoteCOVID-19medicine.diseaseImmunologyBlood Component RemovalCardiology and Cardiovascular MedicinebusinessLipoprotein apheresisJournal of Clinical Lipidology
researchProduct

Metabolic shift of polyphosphate-accumulating organisms with different levels of polyphosphate storage

2012

Previous studies have shown that polyphosphate-accumulating organisms (PAOs) are able to behave as glycogen-accumulating organisms (GAOs) under different conditions. In this study we investigated the behavior of a culture enriched with Accumulibacter at different levels of polyphosphate (poly-P) storage. The results of stoichiometric ratios Gly degraded/HAc uptake, PHB synthesized/HAc uptake, PHV synthesized/HAc uptake and P release/HAc uptake confirmed a metabolic shift from PAO metabolism to GAO metabolism: PAOs with high poly-P content used the poly-P to obtain adenosine tri-phosphate (ATP), and glycogen (Gly) to obtain nicotinamide adenine dinucleotide (NADH) and some ATP. In a test whe…

Accumulibacter Type IIWaste component removalUnclassified drugPhysiologyChemical compositionMicrobial metabolismStorageWastewaterNicotinamide adenine dinucleotidePolyhydroxyalkanoic acidchemistry.chemical_compoundBacteriumBioreactorsPolyphosphatesGlycolysisAnaerobiosisBiomassPolyphosphate-accumulating organismsWaste Management and DisposalAccumulibacter Type IGlycogen accumulating organismPriority journalWater Science and TechnologyFluorescence microscopyPolyhydroxyvalerateSewageGlycogenHydrolysisFluorescence in situ hybridizationEcological ModelingPhosphorusHydrogen-Ion ConcentrationBioaccumulationPollutionStoichiometryWaste treatmentPolyphosphate-accumulating organismsBiodegradation EnvironmentalEnhanced biological phosphorus removalBiochemistryGlycogen-accumulating metabolism (GAM)Nicotinamide adenine dinucleotideAccumulibacter type 1Accumulibacter type 2GlycolysisGlycogenMetabolic Networks and PathwaysAccumulibacterAdenosine triphosphateEnvironmental EngineeringBiologyAcetic acidArticleAssociative storagePolyphosphate-accumulating metabolism (PAM)PolyphosphateGlycogen-accumulating organismsGlycogen-accumulating metabolismsTECNOLOGIA DEL MEDIO AMBIENTEPolyphosphate accumulating organismCivil and Structural EngineeringPolyphosphate-accumulating organisms (PAO)BacteriaPolyphosphateMetabolismIn situ measurementGlycogen-accumulating organisms (GAO)Polyphosphate-accumulating metabolismsNonhumanAmidesCarbonMetabolismchemistryPolyphosphate (poly-P)Bacterial metabolismCell cultureVolatilizationWater Research
researchProduct

Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease

2011

The aim of this paper is to review the latest data on the pharmacological modulation of asymmetric dimethylarginine in human disease. When the terminal nitrogens of the guanidine portion of an arginine become methylated through the action of N-methyl transferases, two chemically close, but physiologically different amino acids are synthesized: symmetric and asymmetric dimethylarginine. The vascular origin of asymmetric dimethylarginine and its inhibitory activity on endothelial nitric oxide synthase give it an important role in certain diseases in which microcirculation is compromised: hypertension, atherosclerosis, inflammatory bowel disease, and diabetes. This review discusses the role th…

Adrenergic Antagonistsmedicine.medical_specialtyAngiotensinsNitric Oxide Synthase Type IIIArginineHypercholesterolemiaPeroxisome Proliferator-Activated ReceptorsHyperhomocysteinemiaReceptors Cytoplasmic and NuclearPeroxisome proliferator-activated receptorPharmacologyArginineBiochemistryNitric oxideDiabetes Complicationschemistry.chemical_compoundInternal medicineDrug DiscoveryAdrenergic antagonistmedicineHumansVascular DiseasesPharmacologychemistry.chemical_classificationVascular diseaseMicrocirculationOrganic Chemistrymedicine.diseaseAngiotensin IIEndocrinologychemistryHypertensionMolecular MedicineKidney DiseasesFarnesoid X receptorHydroxymethylglutaryl-CoA Reductase InhibitorsAsymmetric dimethylarginineCurrent Medicinal Chemistry
researchProduct

Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features

2020

Abstract Background and aims Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by extremely elevated plasma levels of low density lipoprotein cholesterol (LDL-C) and high risk of premature atherosclerotic cardiovascular disease (ASCVD). HoFH is caused by pathogenic variants in several genes, such as LDLR, APOB and PCSK9, responsible for autosomal dominant hypercholesterolemia (ADH), and LDLRAP1 responsible for autosomal recessive hypercholesterolemia (ARH). Aim of this study was the review of the clinical and molecular features of patients with HoFH identified in Italy from 1989 to 2019. Methods Data were collected from lipid clinics and laboratories, …

Adult0301 basic medicinemedicine.medical_specialtyCandidate geneCandidate geneGenotype-phenotype correlationApolipoprotein BCandidate genes; Genotype-phenotype correlations; Homozygous familial hypercholesterolemia; Pathogenic variantsHomozygous familial hypercholesterolemiaGenotype-phenotype correlationsFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosityCandidate genesHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansbiologybusiness.industryPCSK9HomozygoteGenetic disorderPathogenic variantsCandidate genes; Genotype-phenotype correlations; Homozygous familial hypercholesterolemia; Pathogenic variants;medicine.diseasePhenotype030104 developmental biologyEndocrinologyItalyReceptors LDLAutosomal Recessive HypercholesterolemiaMutationLDL receptorbiology.proteinlipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular Medicinebusiness
researchProduct

Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy

2003

Abstract Purpose Recurrent angioedema, characterized by skin swelling, colicky attacks of abdominal pain, and life-threatening laryngeal edema, can be either hereditary or acquired. According to anecdotal reports, it may be associated with use of oral contraceptives and hormone replacement therapy. We investigated potential interactions between these medications and various types of recurrent angioedema in a large cohort of women. Methods Women with recurrent angioedema (n = 516) underwent a thorough medical evaluation. They were then classified by type of angioedema, using standard criteria. Results Of the 516 women, 228 (44%) had used oral contraceptives or hormone replacement therapy, in…

AdultAbdominal painmedicine.medical_specialtyHormone Replacement TherapyPopulationRisk AssessmentSeverity of Illness IndexCohort StudiesAge DistributionRecurrenceimmune system diseasesHumansMedicineHereditary Angioedema Type IIIcardiovascular diseasesAngioedemaRisk factorskin and connective tissue diseaseseducationAgedRetrospective Studieseducation.field_of_studyAngioedemabusiness.industryfood and beveragesRetrospective cohort studyGeneral MedicineMiddle AgedPrognosisDermatologyAbdominal PainSurgeryTransgender hormone therapyFemalemedicine.symptombusinessComplicationContraceptives OralThe American Journal of Medicine
researchProduct

Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation an…

2010

Introduction: Infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α) that has been introduced recently for Behcet's disease (BD) patients who were resistant to standard treatment. The aim of this study was to analyse the functional changes of Vγ9/Vδ2 T lymphocytes in both active and inactive disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity. Methods: We investigated 1) cell expansion, 2) expression of TNFRII receptor, 3) perforin and gamma interferon (IFN) content, 4) release of granzyme A (GrA) and 5) phenotype changes, in vitro and in vivo, in Vγ9/Vδ2 T lymphocytes by means of fluorescence-activated cell sorter …

AdultAdolescentCell SurvivalT cellLymphocyteT-LymphocytesImmunologyGranzymesInterferon-gammaYoung AdultRheumatologyAntigenmedicineImmunology and AllergyHumansReceptors Tumor Necrosis Factor Type IIInterferon gammaCells CulturedAgedCell ProliferationbiologyPerforinBehcet SyndromeAntibodies MonoclonalReceptors Antigen T-Cell gamma-deltaMiddle AgedInfliximabmedicine.anatomical_structurePhenotypeGranzymePerforinAntirheumatic AgentsCase-Control StudiesImmunologybiology.proteinGranzyme ATumor necrosis factor alphaFemalemedicine.drugResearch ArticleArthritis Research & Therapy
researchProduct

Impairment of the extrusion transporter for asymmetric dimethyl-L-arginine: a novel mechanism underlying vasospastic angina.

2012

Abstract A 37-year old male patient presented with frequent angina attacks (up to 40/day) largely resistant to classical vasodilator therapy. The patient showed severe coronary and peripheral endothelial dysfunction, increased platelet aggregation and increased platelet-derived superoxide production. The endothelial nitric oxide synthase (eNOS)-inhibitor N G -nitro- l -arginine methyl ester (L-NAME) reduced superoxide formation in platelets identifying “uncoupled” eNOS as a superoxide source. Oral l -arginine normalized coronary and peripheral endothelial dysfunction and reduced platelet aggregation and eNOS-derived superoxide production. Plasma concentrations of the endogenous NOS inhibito…

AdultBlood PlateletsMalemedicine.medical_specialtyArginineNitric Oxide Synthase Type IIIBiophysicsCoronary VasospasmVasodilationArginineBiochemistryPeripheral blood mononuclear cellAngina Pectorischemistry.chemical_compoundEnosSuperoxidesInternal medicinemedicineHumansPlateletEndothelial dysfunctionEnzyme InhibitorsMolecular BiologybiologyChemistrySuperoxideCell Biologymedicine.diseasebiology.organism_classificationEndocrinologyNG-Nitroarginine Methyl EsterEndothelium VascularIntracellularBiochemical and biophysical research communications
researchProduct

GARP inhibits allergic airway inflammation in a humanized mouse model

2016

Background Regulatory T cells (Treg) represent a promising target for novel treatment strategies in patients with inflammatory/allergic diseases. A soluble derivate of the Treg surface molecule glycoprotein A repetitions predominant (sGARP) has strong anti-inflammatory and regulatory effects on human cells in vitro as well as in vivo through de novo induction of peripheral Treg. The aim of this study was to investigate the immunomodulatory function of sGARP and its possible role as a new therapeutic option in allergic diseases using a humanized mouse model. Methods To analyze the therapeutic effects of sGARP, adult NOD/Scidγc−/− (NSG) mice received peripheral blood mononuclear cells (PBMC) …

AdultCD4-Positive T-LymphocytesMale0301 basic medicinehumanized animal modelImmunologyNodProtein Serine-Threonine Kinasespulmonary inflammationT-Lymphocytes RegulatoryPeripheral blood mononuclear cellregulatory T cellsAllergic inflammationMice03 medical and health sciences0302 clinical medicineImmune ToleranceRespiratory HypersensitivitymedicineAnimalsHumansImmunology and AllergyReceptorLungSensitizationInflammationtolerancebiologybusiness.industryReceptor Transforming Growth Factor-beta Type IIMembrane ProteinsPeripheral toleranceAllergensImmunoglobulin EMiddle AgedasthmaDisease Models Animal030104 developmental biologymedicine.anatomical_structure030228 respiratory systemHumanized mouseImmunologybiology.proteinFemaleAntibodybusinessReceptors Transforming Growth Factor betaAllergy
researchProduct

Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study

2021

Abstract Aims Lomitapide is a lipid-lowering agent indicated as an adjunct therapy for adult homozygous familial hypercholesterolaemia (HoFH). This study evaluated the medium-term effectiveness and safety of lomitapide in a large cohort of HoFH patients in Europe. Methods and results In a multicentre retrospective, observational study including 75 HoFH patients treated with lomitapide in a real-world clinical setting from 9 European countries, low-density lipoprotein cholesterol (LDL-C) changes, adverse events (AEs), and major adverse cardiovascular events (MACE) were assessed. After a median 19 months (interquartile range 11–41 months) of treatment with a mean dosage of 20 mg of lomitapide…

AdultHomozygous Familial HypercholesterolemiaSettore MED/09 - Medicina InternaEpidemiologyAnticholesteremic AgentsHomozygoteMedium-term efficacyCholesterol LDLMedium-term safetyBenzimidazoleLomitapideHomozygous Familial Hypercholesterolemia; atherosclerosis; lomitapide; medium-term efficacy; medium-term safetyHyperlipoproteinemia Type IIHomozygous familial hypercholesterolaemiaRetrospective StudieAtherosclerosiAnticholesteremic AgentHumansBenzimidazolesatherosclerosisCardiology and Cardiovascular MedicineRetrospective StudiesHuman
researchProduct